Compare Tarsons Products with Similar Stocks
Dashboard
Weak Long Term Fundamental Strength with a -39.98% CAGR growth in Operating Profits over the last 5 years
- The company has been able to generate a Return on Equity (avg) of 6.24% signifying low profitability per unit of shareholders funds
With a fall in Net Sales of -8.84%, the company declared Very Negative results in Jun 26
With ROCE of 2.1, it has a Very Expensive valuation with a 2.2 Enterprise value to Capital Employed
Falling Participation by Institutional Investors
Stock DNA
Healthcare Services
INR 1,789 Cr (Micro Cap)
151.00
33
0.00%
0.58
2.37%
2.82
Total Returns (Price + Dividend) 
Latest dividend: 2 per share ex-dividend date: Sep-20-2024
Risk Adjusted Returns v/s 
Returns Beta
News

Tarsons Products Ltd Upgraded to Sell on Technical Improvements Despite Valuation Concerns
Tarsons Products Ltd, a micro-cap player in the healthcare services sector, has seen its investment rating upgraded from Strong Sell to Sell as of 21 September 2026. This change is primarily driven by a marked improvement in technical indicators, even as valuation metrics remain stretched and financial performance continues to disappoint. The nuanced shift reflects a complex interplay of quality, valuation, financial trends, and technical factors that investors must carefully consider.
Read full news article
Tarsons Products Ltd Sees Bullish Technical Momentum Amid Mixed Returns
Tarsons Products Ltd, a micro-cap player in the Healthcare Services sector, has witnessed a significant shift in price momentum and technical indicators, signalling a transition from a mildly bullish to a bullish trend. This development comes alongside a notable 10.91% surge in the stock price, reflecting renewed investor interest and improved market sentiment.
Read full news article
Tarsons Products Ltd Valuation Surges Amid Mixed Market Returns
Tarsons Products Ltd, a micro-cap player in the Healthcare Services sector, has seen its valuation metrics escalate sharply, moving from an already expensive rating to a very expensive status. Despite a robust year-to-date return of 45.7%, the company’s price-to-earnings (P/E) ratio has soared to 152.7, raising questions about price attractiveness relative to historical and peer benchmarks.
Read full news article Announcements 
Response On Clarification Sought On Spurt In Volume Of Tarsons Products Limited
22-Sep-2026 | Source : BSEThe Exchange has sought clarification from the company on September 22 2026 with reference to Movement in Volume.
Clarification sought from Tarsons Products Ltd
22-Sep-2026 | Source : BSEThe Exchange has sought clarification from Tarsons Products Ltd on September 22 2026 with reference to Movement in Volume.
The reply is awaited.
Announcement under Regulation 30 (LODR)-Newspaper Publication
03-Sep-2026 | Source : BSENewspaper Publication for 43rd Annual General Meeting -Completion of dissemination of Notice and Annual Report for FY 2025-26.
Corporate Actions 
No Upcoming Board Meetings
Tarsons Products Ltd has declared 100% dividend, ex-date: 20 Sep 24
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Jun 2026
Shareholding Compare (%holding) 
Non Institution
None
Held by 2 Schemes (0.0%)
Held by 10 FIIs (0.16%)
Sanjive Sehgal (26.98%)
Clear Vision Investment Holdings Pte Limited (23.42%)
22.58%
Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ
QoQ Growth in quarter ended Jun 2026 is -8.84% vs 12.09% in Mar 2026
QoQ Growth in quarter ended Jun 2026 is -134.45% vs -17.06% in Mar 2026
Half Yearly Results Snapshot (Standalone) - Sep'25
Growth in half year ended Sep 2025 is 4.70% vs 12.48% in Sep 2024
Growth in half year ended Sep 2025 is -47.91% vs -13.44% in Sep 2024
Nine Monthly Results Snapshot (Standalone) - Dec'25
YoY Growth in nine months ended Dec 2025 is 6.63% vs 15.98% in Dec 2024
YoY Growth in nine months ended Dec 2025 is -36.33% vs -16.85% in Dec 2024
Annual Results Snapshot (Consolidated) - Mar'26
YoY Growth in year ended Mar 2026 is 7.67% vs 32.40% in Mar 2025
YoY Growth in year ended Mar 2026 is -51.90% vs -30.18% in Mar 2025






